AstraZeneca costs leave 20-month high FTSE 100 exposed to sell-off
Rising research and development and normal running costs at pharma giant AstraZeneca (AZN) gave investors an excuse to take blue-chip profits after the FTSE 100 closed at 20-month highs on Thursday. At lunchtime, the UK's benchmark...
12 November 2021